Belite Bio to Participate in the Leerink Global Healthcare Conference

robot
Abstract generation in progress

Belite Bio, a clinical-stage drug development company, announced its participation in a fireside chat at the Leerink Global Healthcare Conference on March 9, 2026, at 1:00 PM ET. The company focuses on developing novel therapeutics for degenerative retinal diseases and plans to make the webcast available on its investor relations website. Belite Bio’s lead candidate, tinlarebant, is currently undergoing Phase 2/3 and Phase 3 trials for Stargardt disease type 1 and geographic atrophy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments